Introduction {#Sec1}
============

Gastric cancer (GC) is histologically a very heterogeneous disease, and this is reflected in the numerous proposed histological classification schemes \[[@CR1]\]. The temporal development of different histological phenotypes in GC remains unclear. Recent studies suggest that Kirsten Rat Sarcoma Viral Oncogene Homolog *(KRAS)* activation and downstream signalling can impact on the properties and functions of the tumour microenvironment \[[@CR2]\], and thus may influence histological phenotype. Likely mechanisms of *KRAS* activation include *KRAS* mutation (*KRAS*mut) and *KRAS* amplification (*KRAS*amp) \[[@CR3]\].

Mutations in *KRAS* have been identified in many human cancers and result in the constitutive activation of *KRAS* and the receptor tyrosine kinase (RTK) pathway \[[@CR4]\]. The frequency of *KRAS*mut is variable across different cancer types, with the highest frequency in pancreatic cancer (90%) followed by colon (34.6%), lung (16.5%) and ovarian (11%) cancer and the lowest frequencies in cervical (6.6%), prostate (5%) and oesophageal cancer (2%) \[[@CR5]\]. In a review of the literature we identified, on average, only 6.5% of GC have a *KRAS*mut \[[@CR6]\]. In colorectal cancer, routine testing for *KRAS*mut is now implemented as a predictor of response to anti-epidermal growth factor receptor (EGFR) therapy \[[@CR7]\].

Several studies have demonstrated a relationship between *KRAS*mut status and histological phenotype in lung and ovarian cancer. In the subgroup of invasive mucinous adenocarcinoma of the lung, *KRAS* is mutated in up to 86% of cases \[[@CR8]\]. In ovarian cancer, *KRAS*mut has been identified in almost all cases with a mucinous histological phenotype \[[@CR9]\]. The relationship between *KRAS*mut status and histological phenotype in GC remains to be clarified \[[@CR6]\].

The reported frequency of *KRAS*amp is 1--9% in GC \[[@CR10]--[@CR16]\]. There are no reports of a relationship between *KRAS* DNA copy number and histological phenotype in other cancer types and in GC it has not been investigated in a large study. There is increasing recognition of the clinical importance of *KRAS*amp in GC. *KRAS*amp is also associated with a worse survival \[[@CR3], [@CR10], [@CR12]\], whereas *KRAS*mut do not appear to influence survival of GC patients \[[@CR17]\].

Recently, image analysis on lung cancer haematoxylin and eosin (H&E) stained sections using deep learning was predictive of mutation status \[[@CR18]\], thus suggesting that morphological phenotype is reflective of molecular phenotype. Investigating the relationship between *KRAS* activation by *KRAS*mut and/or *KRAS*amp and histological phenotype may provide some insight into gastric adenoma--carcinoma sequence progression and the origin of histological heterogeneity. Based on the studies in lung and ovarian cancer, we hypothesise that *KRAS* activation influences histological phenotype and is associated with a mucinous phenotype in GC. This would suggest that *KRAS* activation is an early event in GC, occurring before the phenotype is determined.

The aim of this multicentre GC study was to investigate the relationship of *KRAS* activation status (*KRAS*mut and/or *KRAS*amp) with the histological phenotype in a large series of GCs from UK, Japan and The Cancer Genome Atlas (TCGA). In addition, the relationship between *KRAS* status, clinicopathological variables, survival and microsatellite instability status was assessed.

Material and methods {#Sec2}
====================

Patients {#Sec3}
--------

### Kanagawa Cancer Center Hospital (KCCH), Yokohama, Japan {#Sec4}

This cohort included 250 patients with TNM stage II/III GC who underwent potentially curative surgery at Kanagawa Cancer Center Hospital (Yokohama, Japan) between 2001 and 2010. One hundred and six (43%) patients were treated with surgery alone, 108 (43%), 22 (9%), 14 (6%) patients received S-1, tegafur--uracil or S-1 combined with other cytotoxic drug therapy, respectively. Demographical, clinical and pathological data were retrieved from hospital records. The study was approved by the Local Research Ethics Committee.

### Leeds Teaching Hospitals NHS Trust (LTHT), Leeds, UK {#Sec5}

This cohort included 277 patients with GC who underwent potentially curative surgery at the Department of Surgery, Leeds General Infirmary (Leeds, UK), between 1970 and 2004. Seven (3%) patients were treated by chemotherapy followed by surgery and the remaining 270 (98%) by surgery alone. Clinical and pathological data were retrieved from histopathology reports, electronic patient hospital records and the Northern and Yorkshire Cancer Registry. The study was approved by the Local Research Ethics Committee (LREC no. CA01/122).

### The Cancer Genome Atlas {#Sec6}

The TCGA stomach adenocarcinoma (STAD) clinicopathological and molecular dataset of 295 patients was obtained from the publically available TCGA database portal \[[@CR19]\].

### Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology (TMGH), Tokyo, Japan {#Sec7}

This cohort included 420 patients with 460 GC who were treated by surgery in the Tokyo Metropolitan Geriatric Hospital between 2000 and 2008. Three hundred and eighty patients had single carcinoma, and 36 had 2 or more carcinomas. Patients with Lynch syndrome were excluded from the current study. None of the patients underwent neoadjuvant chemotherapy. Histopathological examination and medical research were performed with informed written consent by the patients, and this work was approved by the ethics committee of the Tokyo Metropolitan Geriatric Hospital (\#230,225, R16-23).

### Histopathological classification {#Sec8}

pT and pN stages were reported according to 7th edition of the UICC TNM classification for GC \[[@CR20]\].

In all cohorts, H&E stained formalin fixed paraffin embedded (FFPE) tissue sections from the resection specimens were reviewed. In the KCCH and LTHT cohorts, H&E stained slides were scanned at 40 × magnification using an Aperio AT2 scanner for review. In the TCGA cohort, H&E stained slides were viewed online using the cancer digital slide archive (<https://cancer.digitalslidearchive.net/>). In the TMGH cohort, classification was performed using the glass slides.

Histological classification according to JGCA scheme was performed \[[@CR21]\]. Mucinous carcinoma were defined as tumour cells located in mucinous pools comprising an area greater than 50% of the total tumour. GC were classified as signet-ring cell carcinoma when signet-ring cells were present in more than 50% of the tumour volume. In cases where more than one histological phenotype was identified, the most predominant phenotype was recorded, and these GCs were categorised as heterogeneous. JGCA classification was converted to Lauren classification \[[@CR22]\] according to Table [1](#Tab1){ref-type="table"}. As there is no Lauren classification for mucinous GC, we retained mucinous carcinomas as a separate category to distinguish them from other histological types.Table 1Japanese Gastric Cancer Association histological classification of common types of gastric cancers in relation to Lauren classificationHistological classificationLaurenJapanese Gastric Cancer Association (JGCA)IntestinalDifferentiated: Papillary adenocarcinoma (pap) Tubular adenocarcinoma (tub)  Well-differentiated (tub1)  Moderately differentiated (tub2)DiffuseUndifferentiated: Poorly differentiated adenocarcinoma (por)  Non-solid type (por2) Signet-ring carcinoma (sig)MucinousDifferentiated/undifferentiated: Mucinous adenocarcinoma (muc)IndeterminateUndifferentiated: Poorly differentiated adenocarcinoma (por)  Solid type (por1)Table created after personal communication with H. Grabsch, March 12, 2019

### DNA extraction {#Sec9}

The area with the highest tumour cell density was identified on H&E stained sections and the whole tumour area, irrespective of subregions with different histological phenotypes was microdissected after staining with Shandon instant haematoxylin (Thermo Scientific, Cheshire, UK) using a sterile surgical blade. Tumour DNA from FFPE material was extracted from KCCH and LTHT GCs using the QIAmp DNA Micro Kit (Qiagen, Hilden, Germany) as previously described \[[@CR23]\]. DNA concentration was measured by ND-100 Spectrophotometer (Labtech International) and samples were diluted using Tris-EDTA buffer. In the TMGH cohort, DNA was extracted using a phenol--chloroform procedure as described previously \[[@CR24]\].

### *KRAS* gene copy number and data analyses {#Sec10}

*KRAS* copy number status was investigated in KCCH, LTHT and TCGA cohorts.

In the KCCH and LTHT cohort, *KRAS* gene copy number was determined by multiplex ligation-dependent probe amplification (MLPA) using the Salsa-FAM-labeled MLPA reagent kit and probemix P458-A1 or the updated version -B1 (MRC Holland, Amsterdam, The Netherlands) as previously described \[[@CR25]\]. For further details on the *KRAS* probes included in this probemix see Supplementary Table 1. Fragment analysis of the MLPA reaction product was performed using capillary electrophoresis ABI-3130 XL (Applied Biosystems, California, USA) as previously described \[[@CR25]\]. Failed experiments were repeated at least twice before a case was finally excluded from the analyses.

*KRAS* DNA copy number data from 237 KCCH GC has been previously published \[[@CR25]\], but was re-analysed using a different methodology in the current study. The output files (FSA files) from the sequencer were initially imported into Coffalyser.net for fragment analysis and results were exported as csv files. Subsequent analyses were performed using the MLPAInter method, as previously described \[[@CR26]\], implemented in R. Samples were normalised per batch using reference samples processed in each batch. Quality control was performed to exclude samples with low overall intensity, with a large difference in intensity between short probes and long probes, with low intensity of denaturation controls, or high within gene variation, defined as the average of the standard deviation of log-transformed values. Final values were calculated by averaging the peak height of each probe and then averaging the results of replicates. Copy number thresholds were set based on previously published studies \[[@CR25], [@CR27], [@CR28]\], with a DNA copy number \> 1.31 categorised as amplification. This analysis was performed separately for KCCH and LTHT cohorts.

In TCGA, *KRAS*amp were determined by array-based somatic copy number analysis \[[@CR29]\]. Level 3 copy number segmentation data was downloaded from the TCGA data portal \[[@CR19]\] and used to estimate copy number for *KRAS*. Based on previous studies, a LogRatio \> 0.4 was categorised as amplification \[[@CR30]\].

### *KRAS* mutation status {#Sec11}

*KRAS*mut data from a previous study were available for 230 KCCH and 275 LTHT GC patients \[[@CR17]\]. *KRAS*mut testing was performed on an additional 12 KCCH GCs as previously described \[[@CR17]\]. In TCGA, *KRAS*mut status was determined by whole-exome sequencing \[[@CR29]\] and results were downloaded from the TCGA database portal \[[@CR19]\] for 289 patients. In the TMGH cohort, *KRAS* (codon 12 and 13) was examined by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP), using primers and methods previously described \[[@CR31], [@CR32]\].

### Microsatellite instability (MSI) status {#Sec12}

Immunohistochemistry of DNA mismatch repair proteins were used as a surrogate marker of MSI status. Results for MLH1, MSH2, MSH6 and PMS2 were available from 230 KCCH GCs, and MLH1 and MSH2 from 253 LTHT GCs from a previous study \[[@CR17]\]. MLH1, MSH2, MSH6 and PMS2 immunohistochemistry was performed on additional 13 GCs from the KCCH cohort for this study, as previously described \[[@CR17]\].

In TCGA, MSI was determined by a DNA based MSI-Mono-Derived-Dinucleotide Assay using four mononucleotide repeat loci and three dinucleotide repeat loci using a multiplex fluorescent-labeled PCR and capillary electrophoresis \[[@CR29]\]. Results were obtained from the TCGA database portal \[[@CR19]\] for 295 GC patients. MSI-low GCs were grouped with microsatellite stable (MSS) GCs for further analyses following current guidelines \[[@CR33]\].

In the TMGH cohort, mononucleotide repeats *BAT25* and *BAT26* were investigated, as previously described \[[@CR34]--[@CR36]\] and GC were classified as MSS or MSI.

Statistical analyses {#Sec13}
--------------------

All statistical analyses were performed using SPSS software version 23 (SPSS Inc., Chicago, III). The relationship between *KRAS*mut or *KRAS*amp and clinicopathological variables (age, gender, depth of invasion (pT), lymph node status (pN), TNM stage, Lauren classification \[[@CR22]\], JGCA classification \[[@CR21]\], MSI status and morphological heterogeneity status) was assessed using Chi-squared or Fisher's exact test. The relationship between *KRAS*mut and survival in LTHT and KCCH cohorts has been published previously \[[@CR17]\]. Combining all cohorts, the relationship between *KRAS*mut or *KRAS*amp and 5-year overall survival was analysed using the Kaplan--Meier method and differences were assessed using the log rank test. A *p* value of \< 0.05 was considered significant.

Results {#Sec14}
=======

Patient characteristics {#Sec15}
-----------------------

The median (range) age of GC patients was as follows; KCCH: 65 years (35--85 years), LTHT: 72 years (14--96 years), TCGA: 68 years (35--90 years), TMGH: 78 years (51--96 years). For a summary of other patient clinicopathological variables in each cohort see Table [2](#Tab2){ref-type="table"}.Table 2Comparison of clinicopathological variables in each gastric cancer cohortTotal (*n*)\
1282Total (%)KCCH (*n*)\
250KCCH (%)\
20LTHT (*n*)\
277LTHT (%)\
22TCGA (*n*)\
295TCGA (%)\
23TMGH (*n*)\
460TMGH (%)\
36Age (years) \< 653432712249782812342204 ≥ 659367312851199721695844096Gender Male7696017570164591826224854 Female513407530113411133821246T stage pT1272216220711423551 pT21381143172494415276 pT33502834147929155548218 pT4512401676715456752611625N stage pN04893942178731973426357 pN1247195823521964237316 pN2229186727542058205011 pN3306248333843065237416TNM stage I3072403412321224153 II3843097398129116429020 III507401536115155111409220 IV6750114207368Lauren classification Diffuse293238334602273257717 Intestinal6985510342145541565329464 Mucinous514104104207112 Indeterminate229185121562144157817JGCA classification Pap7165293176409 Tub121917187552023812327 Tub240832803281301164013129 Por1229185121562144157817 Por222718632652197124419 Sig6652088321368 Muc514104104207112Morphological heterogeneity Homogenous542431024282301856317338 Heterogeneous7245714058189701083728762*KRAS* mutation status Mutant6851041662810143 Wild type11989523296259942619044697*KRAS* gene copy number Amplified477126178188 - - Other60293196941999220792 - -Microsatellite instability status MSI19916239311264228118 MSS10578422391224882317837982Some variables do not add up to 1282 due to missing data*JGCA* Japanese Gastric Cancer Association, *Pap* papillary adenocarcinoma, *Tub1* well-differentiated tubular adenocarcinoma, *Tub2* moderately differentiated tubular adenocarcinoma, *Por1* poorly differentiated adenocarcinoma solid type, *Por2* poorly differentiated adenocarcinoma non-solid type, *Sig* signet-ring cell carcinoma, *Muc* mucinous adenocarcinoma, *MSI* microsatellite instable, *MSS* microsatellite stable, *KCCH* Kanagawa Cancer Center Hospital, *LTHT* Leeds Teaching Hospital Trust, *TCGA* The Cancer Genome Atlas, *TMGH *Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology

Histological classification of gastric cancer {#Sec16}
---------------------------------------------

Histological classification was available for 1271 GCs. Using the JGCA classification, the most predominant phenotype was moderately differentiated tubular  \[tub2\] (*n* = 408, 32%), followed by poorly differentiated solid type \[por1\] (*n* = 229, 18%), poorly differentiated non-solid type \[por2\] (*n* = 227, 18%), well-differentiated tubular \[tub1\] (*n* = 219, 17%), papillary \[pap\] (*n* = 71, 6%), signet-ring cell \[sig\] (*n* = 66, 5%) and mucinous \[muc\] (*n* = 51, 4%). According to Lauren classification, 293 (23%) GCs were classified as diffuse type, 698 (55%) as intestinal type, 51 (4%) as mucinous and 229 (18%) as indeterminate. Seven hundred and twenty-four GCs (57%) had intratumour morphological heterogeneity (see Table [2](#Tab2){ref-type="table"}).

*KRAS* mutation status and relationship with clinicopathological variables {#Sec17}
--------------------------------------------------------------------------

*KRAS*mut status was available from 1266 GCs (KCCH *n* = 242; LTHT *n* = 275; TCGA *n* = 289, TMGH *n* = 460). In total, 68 (5%) GCs were *KRAS* mutant, with the highest frequency of *KRAS*mut in the TCGA cohort (10%) and lowest frequency in the TMGH cohort (3%), see Table [2](#Tab2){ref-type="table"}. Within the *KRAS*mut GC, the most frequent histological phenotype was intestinal type (*n* = 41, 61%) or tub2 (*n* = 27, 40%) by Lauren and JGCA classification, respectively (see Fig. [1](#Fig1){ref-type="fig"}a). Comparing individual histological subtypes, mucinous phenotype displayed the highest frequency of *KRAS*mut by Lauren (*p* = 0.013) and JGCA (*p* = 0.012) classification, respectively (see Fig. [1](#Fig1){ref-type="fig"}b). *KRAS*mut was more frequent in MSI GC (*p* \< 0.001). For the comparison of *KRAS*mut status and other clinicopathological variables, see Table [3](#Tab3){ref-type="table"}. The 5-year overall survival rate in patients with *KRAS*mut or *KRAS* wild type GC was 63.6% and 54.8%, respectively, *p* = 0.541, see Fig. [2](#Fig2){ref-type="fig"}a.Fig. 1Example of *KRAS* mutated GC with **a** moderately differentiated tubular (tub2) phenotype and **b** mucinous (muc) phenotypeTable 3Comparison of clinicopathological variables and *KRAS* mutation status in all gastric cancer cohorts combined*KRAS* mutation status*p* value*M*\
*nM*\
%WT\
*n*WT\
%Age (years) \< 65134319960.167 ≥ 6555687694Gender Male365723950.225 Female32647594T stage pT1/pT2205388950.639 pT3/pT447680295N stage pN0316455940.158 pN1--pN335573495TNM stage I--II355651950.756 III--IV31653395Lauren classification Diffuse72283980.013 Intestinal41665294 Mucinous6124388 Indeterminate13621594JGCA classification Pap71064900.012 Tub17321297 Tub227737693 Por113621594 Por26321997 Sig126499 Muc6124388Morphological heterogeneity Homogeneous316506940.550 Heterogeneous36568395Microsatellite instability status MSI331716583\< 0.001 MSS323101097Some variables do not add up to 1282 due to missing data*JGCA* Japanese Gastric Cancer Association, *Pap* papillary adenocarcinoma, *Tub1* well-differentiated tubular adenocarcinoma, *Tub2* moderately differentiated tubular adenocarcinoma, *Por1* poorly differentiated adenocarcinoma solid type, *Por2* poorly differentiated adenocarcinoma non-solid type, *Sig* signet-ring cell carcinoma, *Muc* mucinous adenocarcinoma, *MSI* microsatellite instable, *MSS* microsatellite stable, *M* mutated, *WT* wild typeFig. 2Kaplan--Meier plots showing probability of overall survival in GC patients stratified by *KRAS* gene activation status. **a** Kaplan--Meier survival analysis showed no difference in survival when patients were stratified by *KRAS* mutation status. **b** Kaplan--Meier survival analysis showed no difference in survival when patients were stratified by *KRAS* amplification status

*KRAS* amplification and relationship with clinicopathological variables {#Sec18}
------------------------------------------------------------------------

*KRAS* gene copy number status was available from 649 GCs (KCCH *n* = 208, LTHT *n* = 216, TCGA *n* = 225). In total, 47 (7%) GCs had a *KRAS*amp \[TCGA (8%), LTHT (8%) and KCCH (6%)\], see Table [2](#Tab2){ref-type="table"}. Within *KRAS*amp GC, intestinal type (*n* = 23, 50% or tub2 (*n* = 21, 46%) was the most frequent histological phenotype by Lauren and JGCA classification, respectively (see Fig. [3](#Fig3){ref-type="fig"}a). Comparing individual histological subtypes, *KRAS*amp was more frequently found in indeterminate type (*n* = 12, 10%) or por1 (*n* = 12, 10%) phenotype by Lauren and JGCA classification, respectively (see Fig. [3](#Fig3){ref-type="fig"}b). There was no relationship between *KRAS*amp and histological phenotype or any other clinicopathological variables, see Table [4](#Tab4){ref-type="table"}. The 5-year overall survival rate in GC patients with and without *KRAS*amp was 47.6% versus 55.6%, respectively, *p* = 0.166, see Fig. [2](#Fig2){ref-type="fig"}b.Fig. 3Example of *KRAS *amplified GC with **a** moderately differentiated tubular (tub2) adenocarcinoma and **b** poorly differentiated solid-type  (por1) adenocarcinomaTable 4Comparison of clinicopathological variables and *KRAS* copy number status in KCCH, LTHT and TCGA gastric cancer cohorts combined*KRAS* amplified (*n*)*KRAS* amplified (%)*KRAS* other (*n*)*KRAS* other (%)*p* valueAge (years) \< 65218235920.462 ≥ 6526736493Gender Male297383930.792 Female18821992T stage pT1/pT287109930.867 pT3/pT438748493N stage pN074163960.058 pN1--pN340942892TNM stage I--II145262950.061 III--IV32932591Lauren classification Diffuse106168940.480 Intestinal23729893 Mucinous132997 Indeterminate121010790JGCA classification Pap00241000.267 Tub1237097 Tub221920491 Por1121010790 Por29614494 Sig142496 Muc132997Morphological heterogeneity Homogeneous196282940.437 Heterogeneous27831592Microsatellite instability status MSI3390970.093 MSS44849492Some variables do not add up to 822 due to missing data*JGCA* Japanese Gastric Cancer Association, *Pap* papillary adenocarcinoma, *Tub1* well-differentiated tubular adenocarcinoma, *Tub2* moderately differentiated tubular adenocarcinoma, *Por1* poorly differentiated adenocarcinoma solid type, *Por2* poorly differentiated adenocarcinoma non-solid type, *Sig* signet-ring cell carcinoma, *Muc* mucinous adenocarcinoma, *MSI* microsatellite instable, *MSS* microsatellite stable, *KCCH* Kanagawa Cancer Center Hospital, *LTHT* Leeds Teaching Hospital Trust, *TCGA* The Cancer Genome Atlas

Only two GCs from the TCGA cohort had a concurrent *KRAS*amp and *KRAS*mut; one was a mucinous GC, the other was a por2 GC according to JGCA classification.

Discussion {#Sec19}
==========

This is the largest multicentre study to date to investigate the relationship between *KRAS* activation by mutation and/or amplification and histological phenotype in GC. The frequency of *KRAS*amp (7%) was slightly higher than that of *KRAS*mut (5%) which is consistent with other GC studies \[[@CR10], [@CR11], [@CR37]\]. The higher frequency of *KRAS*mut in the TCGA GC cohort compared to the other cohorts could be related to the methodology as TCGA used whole-exome sequencing to test non-hotspot regions, whereas other studies used less-sensitive Sanger sequencing/PCR--RFLP. We found *KRAS*amp and *KRAS*mut were exclusive in \> 99% of GC, which is consistent with previous reports \[[@CR11]--[@CR13], [@CR38]\].

The relationship between *KRAS*mut and histological phenotype has not been investigated in great detail and previous studies were limited by small sample sizes and hence lack of statistical power \[[@CR6]\]. In our study, we identified a relationship between *KRAS*mut and mucinous histological phenotype, which is concordant with higher frequencies of *KRAS*mut being reported in mucinous lung \[[@CR8]\], ovarian \[[@CR9]\] and colorectal cancer \[[@CR39], [@CR40]\]. However, due to the relatively low frequency of GC with mucinous phenotype and *KRAS*mut (12%), it would not be feasible to use the presence of a mucinous phenotype as a predictor for the presence of a *KRAS*mut in GC. The main component of mucinous GCs is extracellular mucin, which consists of high molecular weight glycoproteins regulated by expression of the MUC2, MUC5AC and MUC6 genes in humans \[[@CR41]\]. In mouse models with constitutively activated *KRAS* in the stomach, irregular MUC4+ cells were found with abnormal mucins confirmed by Alcian-blue staining \[[@CR42]\]. Interestingly, our study suggests a relationship between *KRAS*mut and mucinous phenotype, which is characterised by extracellular mucin, but is not related to signet-ring cell type GC, which is characterised by intracellular mucin. Our study confirmed the relationship between *KRAS*mut and the presence of MSI, which our group and others have described previously in a smaller GC cohort \[[@CR43], [@CR44]\].

The prognostic significance of *KRAS*mut in GC remains controversial \[[@CR6]\]. In our study, there was no association with the presence of *KRAS*mut and survival. Interestingly, in lung and colorectal cancer, *KRAS*mut has been associated with a poor prognosis \[[@CR45], [@CR46]\], whereas in ovarian cancer, *KRAS*mut has been associated with an improved prognosis \[[@CR47]\].

The relationship between *KRAS*amp and clinicopathological variables, including histological phenotype in cancer is not well studied. In GC, we found no statistically significant relationship between *KRAS*amp and histological phenotype, or any other clinicopathological variables. In contrast, others found that the presence of *KRAS*amp is associated with a poor prognosis in GC \[[@CR3], [@CR10], [@CR12]\]. This difference might be due to case selection and methodology used.

In our study, we used the JGCA scheme for the histological classification of GC and performed a conversion to the Lauren scheme, which is the most widely used histological classification system in Western countries \[[@CR22]\]. Previous studies investigating the relationship between *KRAS*mut and histological phenotype performed classification according to the Lauren scheme \[[@CR6]\], for which there is no separate category for mucinous GC. The relatively large number of GCs classified as indeterminate according to the Lauren scheme comes from conversion from the JGCA por1 histological phenotype. Direct classification according to the Lauren scheme, would likely result in a higher proportion of GCs classified as either intestinal or diffuse.

In colorectal cancer, *KRAS*mut is known to be an early event in the progression from normal colonic epithelial cell to adenoma, and finally to carcinoma \[[@CR48]\]. The evidence of sequential development by accumulation of genetic alterations, including *KRAS*mut, is still controversial in GC \[[@CR49]--[@CR51]\]. We were unable to make any comments regarding the role of *KRAS *activation in gastric carcinogenesis in our cohort as we did not investigate precancerous lesions in the current study. However, evidence from mouse models suggest that *KRAS*mut is one of the key molecular alterations involved in the development of stomach dysplasia \[[@CR52]\] and GC \[[@CR53]\]. Based on the evidence from other cancer types that *KRAS*mut influence the progression of a mucinous histological phenotype, we therefore speculate based on our results, that *KRAS*mut in GC is an early event in GC development, whereas *KRAS*amp is likely to be a late event occurring after the histological phenotype has been established. This would correspond with experiments in mice expressing oncogenic *KRAS* in combination with E-cadherin and p53 loss, which resulted in a rapid progression of GC compared to wild type mice \[[@CR53]\].

Our study has some limitations. This is a retrospective study. Histological phenotyping was performed on a single slide. Given the high frequency of intra-tumoural morphological heterogeneity in this study and the previously reported intra-tumoural heterogeneity in *KRAS*mut status in GC \[[@CR54]\], the sensitivity of some of the techniques used in the current study may not be sufficient to detect *KRAS* activation in subclones of tumour cells. As we did not perform microdissection of tumour subregions, we cannot comment on *KRAS* status heterogeneity within the same tumour. Furthermore, we used different techniques for DNA extraction, *KRAS*mut status analysis and MSI analysis in different cohorts included in the current study, each with differing sensitivities \[[@CR55], [@CR56]\].

In summary, we identified a relationship between *KRAS*mut and mucinous histological phenotype in GC. The high level of intratumour morphological heterogeneity could reflect *KRAS*mut heterogeneity, which may explain the failure of anti-EGFR therapy in GC.
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